Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 combination therapy in advanced esophageal squamous cell carcinoma
NCT05834543Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2023
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2618 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started May 2023; status: terminated.
02
Drugs
TQB2618
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05834543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05834543.